Newsletter | December 19, 2025

12.19.25 -- The Future Of Biologistics

FEATURED ARTICLE

The Future Of Biologistics

Tom Wells at 4C Associates explores the future of 'biologistics,' or how the packaging, storage, and logistics for biologics might develop over the next two decades, with supply chain implications.

INDUSTRY INSIGHTS

Suspension Cell Culture In Cell And Gene Therapy

Adaptability is crucial for developers as they upscale the production of viral vectors. Explore the benefits of using suspension cell lines and why adherent cell culture shouldn’t be left behind.

CRO Crown Bioscience Adds Kannapolis Site

A new Kannapolis site boosts Crown Bioscience’s preclinical oncology services, expanding its U.S. presence. Learn how this move supports innovation in cancer drug development.

A Framework For Improving Maternity Healthcare In The US (And Elsewhere)

The U.S. has the highest maternal mortality rate among industrialized nations. For Black women, the odds are even worse. Here's why — and what can be done.

A 2025 Survey Report Uncovers The Top 5 Clinical Trial Cost Insights

In this 2025 survey of over 100 U.S. clinical trial participants and caregivers, we reveal that most individuals join trials seeking life-saving treatment, not financial gain.

The Role Of AI In Enhancing Patient Screening For Clinical Trials

AI is transforming clinical trials by streamlining patient recruitment and screening. Discover how advanced technologies are accelerating research and bringing life-saving treatments to market faster.

Overcome Global Medicine Shortages With Innovative Manufacturing

Looking to improve the resilience of your supply chain? Who isn’t? According to a report by Bain & Company, improving supply chain resilience will require redundancy, adaptability, and predictability.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.